Akèy › Sindrom liberasyon sitokin
Etid klinik pou Sindrom liberasyon sitokin ap rekrite nan Etazini
9 etid pou Sindrom liberasyon sitokin ap rekrite patisipan nan sit atravè Etazini.
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07609940Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 10, 2026 · NCT06339177Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT05905328Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT07657312Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Jun 25, 2026 · NCT06447376Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT05972135Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Mar 3, 2026 · NCT05306080Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Ap rekrite
Laj 21 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT07390071Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.